Department of Physiology and Pharmacology, Institute of Biology, Federal University of Pelotas, (UFPel), Campus Universitário, Capão do Leão, S/N, Caixa Postal 354, Pelotas, CEP 96010900, Brazil,
AIDS Behav. 2014 Jan;18 Suppl 1:S85-8. doi: 10.1007/s10461-013-0591-0.
Pharmaceutical care (PC) has been shown to improve adherence to therapeutic interventions as well as improve clinical outcomes. We assessed the predictors of non-adherence to clinical follow-up (i.e., not attending three scheduled routine clinical visits over a 1 year period) among patients who participated in a clinical trial of PC intervention on adherence to HIV antiretroviral therapy uptake (the PC-HIV trial). A total of 332 patients participated: median age was 39 years, 63 % were male, 76 % had CD4 count ≥200 cells/mm³, and 52 % had undetectable viral load. About half, 52.7 %, were non-adherent to clinical follow-up. Identified risk factors for non-adherence were male gender, age <40 years, and being in the trial's "control" group (adjusted odds ratio [AOR] 1.67, 95 % CI 1.05-2.66; AOR 2.21, 95 % CI 1.42-3.47; AOR 1.67, 95 % CI 1.07-2.61, respectively). Younger, male patients may benefit from interventions such as PC, which facilitates engagement in care.
药物治疗（PC）已被证明可以提高对治疗干预的依从性，并改善临床结果。我们评估了参与 PC 干预对 HIV 抗逆转录病毒治疗依从性（PC-HIV 试验）的患者在临床随访（即，1 年内未参加三次预定的常规临床就诊）方面的不依从预测因素。共有 332 名患者参与：中位年龄为 39 岁，63%为男性，76%的 CD4 计数≥200 个细胞/mm³，52%的病毒载量不可检测。约一半，52.7%的患者不遵守临床随访。不依从的风险因素包括男性、年龄<40 岁和处于试验的“对照组”（调整后的优势比 [AOR] 1.67，95%置信区间 [CI] 1.05-2.66；AOR 2.21，95%CI 1.42-3.47；AOR 1.67，95%CI 1.07-2.61）。年轻、男性患者可能受益于 PC 等干预措施，这有助于他们参与治疗。
